Scheduled Intranasal Ketamine

• Status: Not yet recruiting
• Trial end date: 2026-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research is to determine if scheduled intranasal ketamine effects opioid requirements in adult trauma patients with moderate to severe pain in the inpatient setting.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanford Health
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• Patient between aged 18-80 years, present following a traumatic incident, rate pain > 5 on the numeric rating scale (NSR), and require admission to the hospital.

Exclusion Criteria:

• - Patients that arrive at facility intubated

• Patients that received Ketamine in the field

• Patients less than 18 years old or greater than 80 years

• Pregnant or breast-feeding females

• Hemodynamic instability defined as need for vasoactive drugs or Systolic blood pressure >180

• Weight less than 80 pounds or greater than 300 pounds

• Glasgow Coma Scale less than 15

• Current acute head injury resulting in unconsciousness

• Current or history of eye injury

• Current or history of seizures

• Facial or nasal fractures that require nasal precautions

• Current or history of intracranial hypertension

• History of Schizophrenia

• BAC (Blood Alcohol Content) greater than 0.08

• Current alcohol abuse

• Current drug abuse or positive drug screen

• Chronic pain or patients on pain contracts

• Inability to assess pain intensity

• Contraindications or allergies to the treatment

• Patients with hepatic insufficiency

• Prisoners

• Nursing home residents

• Urine drug screen positive for illicit drugs or medications not on their home medication list.

• BAC > 0.08

• Positive pregnancy test